Biomedical Research and Therapy Logo

Biomedical Research and Therapy

Original Research Open Access Logo

CAPE Improves Vanin-1/AKT/miRNA-203 Signaling Pathways in DSS-induced Ulcerative Colitis

Azza M. Metwaly 1
Heba M. Elmoghazy 2
Mohammed Abdalla Hussein 2, * ORCID logo
Amal Abdel-Aziz 1
Samir A Elmasry 1

  1. Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), Sadat University, Egypt
  2. Biochemistry Department, Faculty of Applied Medical Sciences, October 6 University, Egypt
Correspondence to: Mohammed Abdalla Hussein, Biochemistry Department, Faculty of Applied Medical Sciences, October 6 University, Egypt. ORCID: https://orcid.org/0000-0002-1811-2794. Email: [email protected].
Volume & Issue: Vol. 9 No. 9 (2022) | Page No.: 5313-5325 | DOI: 10.15419/bmrat.v9i9.769
Published: 2022-09-30

Online metrics

Statistics from the website

  • HTML Views: 6432
  • PDF Views: 1712
  • XML Views: 1

Statistics from Dimensions

Statistics from PlumX
Copyright © 2022 by the author(s).

This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Introduction: Ulcerative colitis (UC) and other inflammatory bowel diseases (IBDs) are common chronic, inflammatory gastrointestinal diseases. Due to their antioxidant, anti-inflammatory, and antibacterial properties, polyphenols are beneficial in the treatment of IBD. Caffeine acid phenethyl ester (CAPE) has been shown to have cytotoxic, antibacterial, antioxidant, and anti-inflammatory effects. This study focuses on the biochemical and molecular levels of the mode of action of CAPE in DSS-induced UC in rats.

Methods: Thirty male Wistar rats were distributed into five groups, with six rats in each group: group I was administered 3 mL of distilled water orally, group II was administered CAPE (10 mg/kg.b.w.) orally, group III was administered 5% DSS orally, group IV was administered 5% DSS and CAPE (10 mg/kg.b.w.) orally; and group V was administered 5% DSS and sulfasalazine (100 mg/kg b.w.) orally.

Results: Individually, oral treatment with CAPE or sulfasalazine significantly ameliorated body weight, DAI score, and colon length in DSS-induced colitis and raised blood PLT count, NO, NF-kß, and vitamin C levels. In addition, animals given CAPE had a considerable increase in colon GSH, GPx, CAT, and SOD levels compared with rats given DSS. Compared with the DSS control group, colon TBAR, IL-6, and INF-ɣ were lower in the CAPE-treated rats. Histopathological examination revealed that CAPE treatment caused tissue injury and improved vanin-1, AKT, and miRNA-203 genes in the distal colon and triggered apoptosis.

Conclusions: The gastroprotective impact of CAPE was more noticeable than sulfasalazine. CAPE treatment caused biochemical and histopathological improvements, indicating that CAPE may have antioxidant and anti-inflammatory effects in colitis; therefore, CAPE may be a potential therapeutic agent for the amelioration of IBD. This finding is promising for future therapies and research goals.

Keywords: Caffeine acid phenethyl ester dextran sulfate sodium ulcerative colitis antioxidant biomarkers inflammatory mediators Vitamin C and vanin-1

Introduction

Several factors, including genetics, microbiome, and environmental stressors, are the causes of ulcerative colitis (UC)1, 2, 3. In UC, the epithelial cell lining of the colon becomes inflamed4, 5, 6, 7. Dextran sulphate sodium (DSS) is a polysaccharide with varying molecular weight ranging from 5 to 1400 kDa8. Due to its toxicity to colonic epithelial cells, DSS promotes human UC-like diseases, resulting in depressed mucosal barrier function9. Weight loss, diarrhea, and occult blood in the stool are common observations in the DSS-treated rat model10. Many documents have demonstrated the pharmaceutical importance of phytochemicals in reducing UC symptoms, enhancing immune activity, and providing antioxidants that reduce inflammation in animal models11, 12, 13. However, the data indicate a need for further studies to elucidate the benefits and mechanisms of these compounds.

Caffeic acid phenethyl ester (CAPE) is a major active phenolic compound of some types of propolis14, 15. It has been shown to be protective against oxidative stress-mediated tissue damage16, 17, 18, 19. CAPE has been associated with a variety of and pharmacological effects20, 21, 22, 23, and there have been reports of its gastroprotective activity in animal models. In addition, its anticancer properties were observed in the skin of mice treated with bee propolis and exposed to 12-O-tetradecanoylphorbol-13-acetate24, 25.

Our findings indicate that the presence of vanin-1 in tissues of the epithelium influences the perception of stress26 by innate immune cells as an inhibitor of inflammatory processes and the treatment of colitis27. In addition, research indicates the upregulation of miRNA 203 and AKT gene expression in certain inflammatory tissues and organs28, 29, 30. As a measure of our interest research program in the treatment of inflammatory diseases31, 32, 33, 34, 35, 36. In the present study, we aimed to evaluate the therapeutic potential of CAPE in DSS-induced UC in rats.

Methods

Chemicals

All chemicals were purchased from Sigma Aldrich, Germany.

- Caffeic acid phenethyl ester (97%) powder: Formula [CHO] molecular weight (284.31), CAS. No. (104594-70-9).

- Dextran sulfate sodium (98%) powder: Formula [(CHNaOS)n], molecular weight (>500,000), CAS. No. (9011-18-1).

- Sulfasalazine (99%) powder: Formula (CHNOS), molecular weight (398.394), CAS. No. (599-79-1).

Animals

Male albino rats weighing 150 ± 10 g each were donated by the National Cancer Institute Animal House at Cairo University in Giza, Egypt. They were kept in plastic cages with stainless steel covers at a humidity level of 55 — 60% and a temperature of 22 °C in a light-controlled environment. The animals were maintained for 2 weeks to adapt and were provided regular feed and water at will.

Design of experiment

This experiment was designed to evaluate the gastroprotective effect of CAPE in DSS-induced UC. According to the guidelines of the Faculty of Applied Health Sciences Committee, the present study was design. The treatment grouping is described in Table 1.

Table 1

Description of treatment groups

Group

NO.

Groups

Treatment description

I

Normal control

Received 3 mL of distilled water, orally for 15 days.

II

CAPE

(10 mg/kg.b.w.)

Received 10 mg / kg bw. CAPE, orally, daily for 15 days36.

III

Positive control

DSS, 5% in distilled water

Received DSS, 5% orally, for 15 days37.

IV

DSS + CAPE

Received DSS + CAPE, orally, for 15 days

V

DSS + Sulfasalazine (100 mg/kg b.w.)

Received DSS + sulfasalazine (100 mg/kg b.w.), orally, for 15 days37.

Calculation of disease activity index

In experimental colitis, the disease activity index (DAI) was calculated according to the method outlined by Bang and Lichtenberger38.

Sample collection

On day 16, 1 day after the last dose, blood samples were collected in tubes containing heparin from the retroorbital venous plexus of each animal. Heparinized blood samples were divided into two parts: the first part was used to estimate PLT count using a Sysmex KX-21N automated hematology analyzer (Sysmex Corp., Kobe, Japan)39, and the second part was centrifuged at 1000 g for 20 min. Separated plasma was used to estimate plasma levels of NF-κB using an ELISA kit (MyBioSource Inc., San Diego, CA, USA, 92195-3308), NO using the calorimetrically calibrated diagnostic kit, interleukin 6 (IL-6) using an ELISA kit (Abcam plc, USA), and vitamin C (Vit. C) using an ELISA kit (Novus kits, Novus Biologicals, LLC, California, USA).

At the end of the experiment, the colon of each animal was excised, washed with phosphate-buffer saline (PBS), gently stretched, and the distance between the colocecal junction and the distal end of the rectum was measured40. The distal sections of the colons were then separated; one piece was used for histopathological analysis, and the other piece was kept frozen at 80 °C until biochemical analysis of TBARS, GSH, SOD, and CAT41, 42, 43, 44 using colorimetric methods in the diagnostic kit. In addition, the IFN-γ content was determined using an ELISA kit (Abcam plc, USA).

Real-time PCR

Using the RNA-spinTM (QiaGen GmbH, Hilden, Germany), total RNA from colon tissues was extracted45. As instructed by the manufacturer, cDNA was used for qPCR using the SYBR Green PCR master mix (iNtRON Biotechnology, Korea). The reverse transcription kit was used to produce cDNA from 1 – 5 g total RNA (Applied Biosystems, Foster City, CA). The sequences of the genes evaluated (vanin-1, AKT, and miRNA-203) and the housekeeping primer used in RT-PCR, β-actin (Primer Design Ltd, USA), are shown in Table 2.

Table 2

The primer sequences

Gene

Sequences

Vanin-1

forward

5'-AACTGGATACCCTGTGATAACCC-'3

reverse

5'- GTCTCCCATGTTCGCCACAA-'3

AKT

forward

5'-CCCTGCTCCTAGTCCACCA–'3

reverse

5'-TGTCTCTGTTTCAGTGGGCTC-'3

miRNA-203

forward

5'- GGGGTGAAATGTTTAGGAC-'3

reverse

5'- CAGTGCGTGTCGTGGAGT-'3

β-actin

(housekeeping)

forward

5'-TGACTGACTACCTCATGAAGATCC-'3

reverse

5'-TCTCCTTAATGTCACGCACGATT-'3

Histological examination

A sample of colon tissues was collected and fixed in 10% neutral buffered formalin. It was then dehydrated in ascending graders of ethyl alcohol (50–100%), cleared in xylene and embedded in melted paraffin wax (MP 59), embedded in paraffin as blocks, and 5–6-micron-thickness sections were cut using a rotary microtome46. The paraffin sections were stained and exanimated using a light microscope (Olympus, Münster, Germany). A photomicrograph of the colon tissue was taken at 400 x magnification.

Statistical analysis

Data are presented as mean ± standard deviation (SD) for six measurements for both spectrophotometric measurements and ELISA. However, there are three separate determinations for PCR analysis of gene expression. All data were analyzed using SPSS version 20 software47. The one-way analysis of variance (ANOVA) test was used to assess the hypotheses. Statistical significance was defined as P < 0.05.

Figure 1

Effect of CAPE and sulfasalazine on disease activity index in DSS induced colitis groups of rats for 15 days. Data was expressed as mean ± SEM (n = 6). The obtained values were significantly different at P ≤ 0.05.

Figure 2

Effect of CAPE and sulfasalazine on colon length in DSS treated rats. Data was expressed as mean ± SEM (n = 6).

Figure 3

Effect of CAPE and sulfasalazine on colon Vanin-1, AKT and miRNA-203 gene expression in DSS-treated rats. Representative bar diagram of three independent experiments is presented. Data followed by the same letter are not significantly different at P ≤ 0.05.

Table 3

Effect of CAPE and sulfasalazine on the body weight every 5 days of DSS treated rats

No.

Groups

Number of days/

Body weight of rats(g)

1

5

10

15

(I)

Normal control

3 mL of distilled water, orally

160.42 ± 3.72bA

163.72 ± 5.08aA

169.79 ± 7.69

174.63 ± 3.24cC

(II)

CAPE

(10 mg/kg.b.w.)

162.29 ± 8.53A

166.63 ± 8.23AB

170.58 ± 10.54 C

175.69 ± 8.06cD

(III)

Positive control

DSS, 5% in distilled water

158.15 ± 10.78 aA

160.50 ± 9.29aA

161.57 ± 10.73 a

161.99 ± 4.95 aB

(IV)

DSS + CAPE

160.43 ± 10.45 A

163.01 ± 7.72aA

168.33 ± 5.28ab

172.37 ± 9.62 C

(V)

DSS + Sulfasalazine (100 mg/kg b.w.)

159.73 ± 4.47aA

162.07 ± 6.14aAB

165.70 ± 8.00aBC

167.73 ± 6.03aC

Table 4

Effect of CAPE and sulfasalazine on blood PLT count as well as plasma NO, NF-kβ and Vit.C in DSS-treated rats

Groups

Treatment Description

PLT

(103/mL)

NO

(ng/mL)

NF-kβ (ng/mL)

Vit. C

(µmol/L)

I

Normal control

3 mL of distilled water, orally

261.27 ± 23.18 c

10.79 ± 1.87 a

0.81 ± 0.10 a

83.13 ± 7.96 d

II

CAPE

(10 mg/kg.b.w.)

265.33 ± 18.62 c

9.67 ± 0.54 a

0.93 ± 0.16 a

82.04 ± 5.46 d

III

Positive control

DSS, 5% in distilled water

209.28 ± 12.08 a

36.13 ± 4.39 d

3.51 ± 0.37 d

59.76 ± 6.46 a

IV

DSS + CAPE

265.00 ± 26.38 c

14.52 ± 3.30 b

1.36 ± 0.22 b

77.13 ± 6.14 c

V

DSS + Sulfasalazine (100 mg/kg b.w.)

217.58 ± 14.00 B

21.94 ± 2.56 c

2.40 ± 0.31 c

65.98 ± 5.25 b

Table 5

Effect of CAPE and sulfasalazine on colon GSH, GPx, CAT and SOD in DSS-treated rats

Groups

Treatment Description

GSH (nmole/mg protein)

GPx

(U/mg protein)

CAT (U/mg protein)

SOD (U/mg protein)

I

Normal control

3 mL of distilled water, orally

29.89 ± 2.79d

25.97 ± 2.85d

32.67 ± 2.75d

97.44 ± 11.13 d

II

CAPE

(10 mg/kg.b.w.)

30.71 ± 3.21d

22.39 ± 3.77cd

35.48 ± 3.62d

96.17 ± 9.49 d

III

Positive control

DSS, 5% in distilled water

13.64 ± 2.65a

8.98 ± 0.84a

13.82 ± 2.27a

53.09 ± 6.99 a

IV

DSS + CAPE

23.04 ± 3.20 c

19.28 ± 3.21c

27.50 ± 2.23 c

79.25 ± 6.48 c

V

DSS + Sulfasalazine (100 mg/kg b.w.)

17.45 ± 3.35b

13.78 ± 2.65

21.60 ± 2.44b

61.19 ± 5.82b

Table 6

Effect of CAPE and sulfasalazine on colon TBARs, IL-6 and INF-γ in DSS-treated rats

Groups

Treatment Description

TBARs

(nmol/mg protein)

IL-6

(pg/mg protein)

INF-γ (pg/mg protein)

I

Normal control

3 mL of distilled water, orally

70.34 ± 5.72 a

25.71 ± 4.49 a

0.41 ± 0.06 a

II

CAPE

(10 mg/kg.b.w.)

68.83 ± 5.81 a

27.85 ± 2.58 a

0.38 ± 0.05 a

III

Positive control

DSS, 5% in distilled water

142.71 ± 8.73 d

46.59 ± 4.69 d

1.46 ± 0.13 d

IV

DSS + CAPE

93.06 ± 8.06 b

33.08 ± 4.13 b

0.64 ± 0.08 b

V

DSS + Sulfasalazine (100 mg/kg b.w.)

114.65 ± 11.44 c

40.17 ± 4.25 c

1.14 ± 0.17 c

Figure 4

Effect of CAPE and sulfasalazine on histological changes of colon tissues of different groups. (a): Group I, (b): Group II: Was administrate CAPE (10 mg/kg.b.w.), (c): Group III: DSS (50%), (d): Group IV: Was administrate DSS (5%) + CAPE (10 mg/kg.b.w.), (e): Group V: Was administrate DSS (5%) + Sulfasalazine (100 mg/kg b.w.).

Results

Effect of CAPE and sulfasalazine on the body weight of DSS-treated rats

Table 3 shows non-significant changes in body weight of CAPE (10 mg/kg.b.w.)-treated rats (group II) as compared with normal control rats (group I). Additionally, there was a significant depletion of 7.2% body weight in rats treated with DSS (5%) (group III) as compared with the control group after 15 days of oral administration (P< 0.05).

In contrast, administration of CAPE (10 mg/kg.b.w.) to DSS rats produced a significant increase in body weight by 60.40 % compared with the DSS-treated control group (P < 0.05). Administration of sulfasalazine (100 mg/kg b.w.) produced a non-significant increase in body weight in DSS-treated rats by 3.54 % when compared to the DSS-treated control group of rats.

Effect of CAPE and sulfasalazine on disease activity index in rats with DSS-induced colitis

The results in Figure 1 indicate a non-significant change in the DAI of CAPE-treated rats (group II) as compared to normal control rats (group I). However, the present data show a significant change in the DAI score after DSS treatment compared with the DAI of the control group. Treatment with CAPE (10 mg/kg.b.w.) and sulfasalazine produced significantly improved DAI scores in DSS-treated rats as compared with the group treated with DSS alone (P < 0.05).

Effect of CAPE and sulfasalazine on colon length in DSS-treated rats

The colon length of CAPE-treated normal rats (group II) was non-significantly changed when compared with the normal rats (Figure 2). Compared with the normal group of rats, treatment with DSS (5%) resulted in a significant reduction in colon length by 24.7 %. Furthermore, administration of CAPE to the DSS-treated group produced a significant increase in colon length by 25.38 % when compared with the DSS-treated control group (P < 0.05). However, the administration of sulfasalazine to DSS-treated rats produced a significant increase in colon length by 12.78% compared with the DSS-treated control group (P < 0.05).

Effect of CAPE and sulfasalazine on blood PLT count and plasma NO, NF-kβ, and vitamin C in DSS-treated rats.

Administration of CAPE to normal rats produced non-significant changes in plasma PLT, NO, NF-kβ, and Vit. C when compared with normal rats (Table 4).

Compared with normal rats, DSS treatment (5%) resulted in a significant reduction in blood PLT count and plasma Vit. C levels by 19.89% and 28.11%, respectively, and a significant increase in plasma NO and NF-kβ by 234.84% and 333.30%, respectively (P < 0.05).

Additionally, compared with the DSS-treated control group, CAPE treatment resulted in significantly elevated PLT count and plasma Vit. C levels by 26.62% and 29.06%, respectively, and a significant decrease in plasma NO and NF-kβ by 59.81% and 61.25%, respectively (P < 0.05).

Sulfasalazine administration significantly increased blood PLT and plasma Vit. C levels by 3.96% and 10.4%, respectively, and produced a significant increase in plasma NO and NF-kβ by 39.27% and 31.62%, respectively, when compared with the DSS-treated control group (P < 0.05) (Table 4).

Effect of CAPE and sulfasalazine on colonic GSH, GPx, CAT, and SOD in DSS-treated rats

Administration of CAPE to normal rats produced nonsignificant changes in colon GSH, GPx, CAT, and SOD when compared with normal rats. However, compared with normal rats, DSS (5%) treatment resulted in a significant reduction in colon GSH, GPx, CAT, and SOD of 54.36%, 55.42%, 57.69%, and 45.51%, respectively. Furthermore, administration of CAPE to rats treated with DSS produced a significant increase in colon GSH, GPx, CAT, and SOD by 68.91%, 114.64%, 98.9%, and 49.27%, respectively, when compared with rats treated with DSS alone (P < 0.05) (Table 5).

Treatment of rats with sulfasalazine (100 mg/kg b.w.) produced a significant increase in colon GSH, GPx, CAT, and SOD by 27.93%, 53.45%, 56.29%, and 15.25%, respectively, compared with the DSS-treated control group (P < 0.05).

Effect of CAPE and sulfasalazine on colonic thiobarbituric acid-reactive substances (TBARs), interleukin 6 (IL-6), and interferon γ (INF-γ) in DSS-treated rats

Table 6 shows the effects of CAPE and sulfasalazine individually on colon TBARs, IL-6, and INF-γ in normal and DSS-treated rats. Oral administration of normal rats with CAPE showed nonsignificant changes in colonic TBAR, IL-6, and INF-γ when compared to normal rats. In contrast, oral administration of DSS (5%) resulted in a significant increase in colon levels of TBAR, IL-6, and INF-γ by 102.88%, 81.21%, and 256.09%, respectively (P < 0.05).

Compared with the DSS-treated control group, CAPE administration in the X group resulted in a significant reduction in colonic TBAR, IL-6, and INF-γ by 35.22%, 28.99%, and 56.10%, respectively. Furthermore, administration of sulfasalazine (100 mg/kg b.w.) significantly decreased colonic TBARs, IL-6, and INF-γ by 19.66%, 13.77% and 21.91%, respectively, when compared with the DSS-treated control group (P < 0.05).

Effect of CAPE and sulfasalazine on colonic vanin-1, AKT, and miRNA-203 gene expression in DSS-treated rats

Figure 3 shows the individual effects of CAPE and sulfasalazine on the expression of the vnin-1, AKT and miRNA-203 genes in normal rats treated with DSS. Treatment of normal rats with CAPE (10 mg/kg.b.w.) produced a nonsignificant change in colon vanin-1, AKT, and miRNA-203 gene expression.

When compared with the normal control group, oral administration of DSS (5%) resulted in a significant increase in colon levels of vanin-1, AKT, and miRNA-203 gene expression by 416.66%, 511.65%, and 761.4%, respectively (P < 0.05).

However, compared with the DSS-treated control group, CAPE treatment resulted in a significant reduction in colonic expression of vanin-1, AKT, and miRNA-203 gene by 55.35%, 52.53%, and 72.41%, respectively. Furthermore, the administration of sulfasalazine to rats treated with DSS significantly decreased the expression of vanin-1, AKT, and miRNA-203 genes in the colon by 74.95%, 73.65%, and 55.17%, respectively, compared with the control group (P < 0.05).

Effect of CAPE and sulfasalazine on histological alterations in colon tissues

Figure 4(a-e) shows the individual effects of CAPE and sulfasalazine on colon histopathology of normal and DSS-treated rats.

In Figure 4a&b, histopathological examination of normal and CAPE-treated groups (I&II) revealed intact surface epithelium (black arrows) and regular glands with adequate mucin production (blue arrows). The lamina propria did not show inflammatory cell aggregates.

In Figure 4c, colon histopathological examination of DSS-treated rats revealed surface erosions and ulcerations (black arrows). Many glands were replaced by inflammation, with mucin depletion (blue arrows). Many lymphoid aggregates (stars) are observed.

Furthermore, oral administration of CAPE to rats treated with DSS produced an intact surface epithelium (black arrows); mucin depletion was partially corrected (blue arrows), and few focal lymphoid aggregates were still observed (stars) compared with rats treated with DSS.

However, histological examination of rats treated with sulfasalazine/DSS showed a partly eroded surface epithelium (black arrows) with glandular mucin depletion in many glands (blue arrows); large lymphoid aggregates were still seen (stars).

Discussion

UC is believed to be a TH2-mediated inflammatory disease, while Crohn's disease is thought to be a TH1-mediated inflammatory disease48. In animal models, the inflammatory imitate UC mediated by TH1 and TH 2 was elevated49.

Numerous studies have shown that polyphenols and flavonoids can be used therapeutically to prevent invasion and metastasis of colorectal cancer cells50, 51.

In that study, we suggested that CAPE inhibited the expression of inflammatory mediators and biomarkers of oxidative stress. A recent study reported a previously unknown mechanism in which CAPE could inhibit invasion and migration by modulating the MMP-2 and MMP-9 signaling pathways52.

Effect of CAPE and sulfasalazine on the body weight of DSS-treated rats

In UC animal models, the degree of inflammation is measured by determining the daily change in body weight of the animals during each experiment and measuring the length of the resected colon53, 54. Although weight loss alone is a poor predictor of well-being55, it is still accepted that weight loss >20% is a criterion for euthanasia and an indication that the experimental design may be too aggressive55. The three primary symptoms of IBD in DSS-induced rats with colitis were considerable weight loss, bloody diarrhea, and shortening of the colon56, 57. In addition, in rats treated with DSS, colon shortening may be related to thickening due to edema and infiltration of inflammatory cells into the lamina propria and submucosa58.

Effect of CAPE and sulfasalazine on colonDAI score and length in DSS treated rats

In our investigation, treatment of rats with DSS for 15 days caused acute colitis with an elevated DAI score and a decreased colon weight/length ratio. A substantial correlation between the DAI score and inflammation in DSS-induced acute and chronic colitis has been reported by Bullich .57 Following treatment with CAPE, colon length, DAI score, and body weight improved. Many researchers have reported the antioxidant, anti-inflammatory, anticancer, prebiotic, immunomodulatory, and gastroprotective properties of polyphenols and their metabolites59, 60. CAPE treatment led to a marked reduction in the inflammatory infiltrate in both the lamina propria and the submucosa and protected against changes in colon length in a dose-dependent manner. Espíndola .52 showed that CAPE inhibits the release of inflammatory cytokines from human hepatocellular carcinoma cells.

Effect of CAPE and sulfasalazine on blood PLT count and plasma NO, NF-kβ, and Vit. C in DSS-treated rats

In the present study, we observed a depletion of blood PLT levels in DSS-treated rats. Our results were in line with those reported by Zamora .61 and Honjo .,62 who showed that UC patients had the lowest levels of PLT and Vita. C due to the production of inflammatory mediators NO and NF-kβ63 and the depletion of endogenous antioxidant biomarkers (i.e., Vit. C), which reduced the binding of PLTs to monocytes through the membrane, favoring an inflammatory response in UC patients with onset flare. The PLT changes in DSS-treated rats were restored upon treatment with CAPE and sulfasalazine. CAPE exhibited potent antioxidant activity by restoring the levels of PLT, NO, NF-kβ, and Vit. C. Our results are in line with the results of Gupta 64 and Nakashima .65, who noticed that phenolics significantly reduced levels of inflammatory mediators, thereby suppressing their inflammatory response in UC. Our results suggest that CAPE treatment decreases the expression of NO and NF-kβ, increases the production of Vit. C, and ameliorates intestinal mucosal barrier dysfunction in UC.

Effect of CAPE and sulfasalazine on colon GSH, GPx, CAT, and SOD in DSS-treated rats

In the present study, we noticed depletion of colon GSH, GPx, CAT, and SOD in DSS-treated rats. Our results were in line with the results reported by Zieliska et al.66, who observed a significant decrease in GSH, GPx, CAT, and SOD levels in patients with IBD when compared with controls. Our results indicate that the administration of CAPE significantly improves macroscopic damage, colon length, increases the activity of GPx, CAT, and SOD, depresses TBARs and NO levels, and increases GSH levels in the colon tissues of experimental colitis. Many articles have shown that the administration of flavonoids and polyphenols modulates the levels of antioxidant biomarkers and inflammatory mediators67, 68.

Effect of CAPE and sulfasalazine on colonic TBARs, IL-6, and INF-γ in DSS-treated rats

Our study indicated the elevation of TBAR, IL-6, and INF-γ levels in the colon tissues of experimental colitis. Yan .69 reported elevation of TBAR, IL-6, and INF-γ levels in colon tissue. These markers increase the inflammatory response of IL-6, INF-γ, NF-κB, destructive enzymes, and TBARs that cause damage to colon tissue70. In our study, CAPE significantly ameliorated tissue damage, IL-6, INF-γ, NF-κB, and TBARs in rats treated with DSS. Furthermore, our results indicate that DSS upregulates colon vanin-1 gene expression in DSS-treated rats. Our results were confirmed by the results of Gensollen .71, who reported vanin-1 upregulation in the intestinal tract in DSS-induced colitis. Our study suggests that elevation of vanin-1 gene expression in DSS-treated rats is a direct target for NF-κB in the colon, and this could be related to susceptibility to UC.

Effect of CAPE and sulfasalazine on colon vanin-1, AKT, and miRNA-203 gene expression in DSS-treated rats

Colon Akt gene expression was significantly upregulated in DSS-treated in rats. Our results were in line with a study by Li .72, who reported upregulation of Akt in DSS-treated rats. Furthermore, the Akt signaling pathway was significantly inhibited by CAPE administration, leading to the recovery of intestinal microbiota diversity. Our results indicated the downregulation of colon Akt gene expression by CAPE administration due to its inhibitory activity against colon NF-κB production in DSS-treated rats. Additionally, our study revealed upregulation of miRNA-203 gene expression in DSS-treated rats. Tian .73 studied the effect of inflammation on miRNAs and found that the mucosa of UC patients that was infiltrated with inflammatory cells had elevated miRNA levels, while the levels were reduced to non-inflammatory levels in patients under remission. Further investigation revealed the role of miRNA in suppressing inflammatory mediator genes within colonic epithelial cells, all implicated in IBD74. However, miR-203 downregulation was observed in DSS-treated rats after oral CAPE administration. An association between vanin-1 and AKT suggests that overexpressed vanin-1 decreases the extent of AKT74 phosphorylation. Furthermore, miR-203 can activate the Akt signaling pathway through IL-8 in the regulation of radioresistance in nasopharyngeal carcinoma cells75. Moreover, the AKT signaling pathway has been shown to be effective in preventing ventilator-induced lung injury76. Our findings suggest regulation of miR-203 gene expression due to inhibition of IL-6, INF-γ, and NF-κB production and vanin-1 and Akt gene expression by CAPE administration.

Our results support and indicate downregulation of colon vanin-1 gene expression in DSS-treated rats after CAPE administration for 15 days due to inhibition of colon NF-κB levels.

Effect of CAPE and sulfasalazine on histological changes in colon tissues

In rats treated with DSS, histological analysis of colon tissue indicated altered mucosal architecture and inflammation. Our observations of microscopic changes were consistent with a large body of research on DSS-induced UC models in rats77. CAPE inhibits changes in colon architecture and length and significantly reduces inflammatory infiltration in both the lamina propria and submucosa.

CAPE treatment significantly decreased colon injury and contributed to the anti‑inflammatory and anti‑apoptotic effects. Furthermore, the anti‑inflammatory and anti‑apoptotic activities of CAPE and its effects on vanin-1, AKT, and miRNA-203 gene expression in IBD rats has not been previously documented, and this study may be the first of its kind.

Conclusions

The current study used biochemical and molecular analysis to show that IBD is associated with increased levels of oxidative stress and apoptosis. The data show that IL-6, INF-α, and NF-kβ are actively involved in gut mucosal inflammation in DSS-treated rats. Furthermore, we found significant improvement in miRNA-203, vanin-1, and Akt gene expression in DSS-treated rats. The potential benefits of CAPE on colon lipid peroxidation, inflammatory mediators, and antioxidant systems led researchers to hypothesize that it would be a viable choice for treating IBD.

Abbreviations

AKT: Protein kinase B, CAPE: caffeic acid phenethyl ester, CAT: catalase, DAI: disease activity index, DSS: dextran sulfate sodium, GPx: glutathione peroxidase, GSH: reduced glutathione, IL-6: interleukine-6, INF-γ: interferon-γ, IBD: inflammatory bowel disease, NO: nitric oxide, NF-kβ: nuclear factor kappa, PLT: platelet count, SOD: superoxide dismutase, TBARs: thiobarbituric acid reactive substances, Vit. C: vitamin C.

Acknowledgments

None.

Author’s contributions

All authors contributed significantly to this work, read, and approved the final manuscript.

Funding

None.

Availability of data and materials

Supporting data, including analytical (colorimetric ELISA-PCR) data, will be available to demonstrate the hepatoprotective activity of morin against paracetamol-induced liver toxicity.

Ethics approval and consent to participate

Data collection was ethically approved by the Research Ethics Committee of the Faculty of Applied Medical Sciences, October 6 University, Egypt (No. 20210614). lab studies formed the basis of this research, no human volunteers were used.

Consent for publication

The authors granted their permission for their personal information to be used in the article.

Competing interests

The authors declare that they have no competing interests.

References

  1. A. Salah, A. Hussein, S. Hassan, M.A. Hussein, K. Bassiouny. Green Synthesis of RES-CMCS: A Promising Modulator of the GLUT-4/Leptin Signaling Pathway in HFD-induced Insulin Resistance. Biomedical Research and Therapy 2022; 9(7): 5166-78.
  2. T. Pan, H.Y. Guo, H. Zhang, A.P. Liu, X.X. Wang, F.Z. Ren. Oral administration of Lactobacillus paracasei alleviates clinical symptoms of colitis induced by dextran sulphate sodium salt in BALB/c mice. Beneficial Microbes 2014; 5(3): 315-22.
  3. G. Li, Z. Liu, F. Ren, H. Shi, Q. Zhao, Y. Song. Alterations of gut microbiome and fecal fatty acids in patients with polycystic ovary syndrome in central China. Frontiers in Microbiology 2022; 13: 911992.
  4. L. Zhou, Z. Ni, J. Yu, W. Cheng, Z. Cai, C. Yu. Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome. Frontiers in Endocrinology (Lausanne) 2020; 11: 628.
  5. L. Cheng, H. Jin, Y. Qiang, S. Wu, C. Yan, M. Han. High fat diet exacerbates dextran sulfate sodium induced colitis through disturbing mucosal dendritic cell homeostasis. International Immunopharmacology 2016; 40: 1-10.
  6. K. Wang, G. Han, Y. Dou, Y. Wang, G. Liu, R. Wang. Opposite role of tumor necrosis factor receptors in dextran sulfate sodium-induced colitis in mice. PLoS One 2012; 7(12): e52924.
  7. H. Zhang, Y. Sun, K. Li, J. Zhang, X. Chen. Multiple lesions at different stages of pyoderma gangrenosum in a crohn's disease patient. Clinical, Cosmetic and Investigational Dermatology 2022; 15: 1593-6.
  8. H. Laroui, S.A. Ingersoll, H.C. Liu, M.T. Baker, S. Ayyadurai, M.A. Charania. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One 2012; 7(3): e32084.
  9. E. Piccinin, M. Cariello, S. De Santis, S. Ducheix, C. Sabbà, J.M. Ntambi. Role of oleic acid in the gut-liver axis: from diet to the regulation of its synthesis via stearoyl-CoA desaturase 1 (SCD1). Nutrients 2019; 11(10): 2283.
  10. L.M. Mar-Solís, A. Soto-Domínguez, L.E. Rodríguez-Tovar, H. Rodríguez-Rocha, A. García-García, V.E. Aguirre-Arzola. Analysis of the Anti-Inflammatory Capacity of Bone Broth in a Murine Model of Ulcerative Colitis. Medicina (Kaunas, Lithuania) 2021; 57(11): 1138.
  11. L. Zhu, P. Gu, H. Shen. Gallic acid improved inflammation via NF-κB pathway in TNBS-induced ulcerative colitis. International Immunopharmacology 2019; 67: 129-37.
  12. W. Fang, S. Zhu, Z. Niu, Y. Yin. The protective effect of syringic acid on dextran sulfate sodium-induced experimental colitis in BALB/c mice. Drug Development Research 2019; 80(6): 731-40.
  13. S. Muthusami, I.K. Ramachandran, K.N. Babu, S. Krishnamoorthy, A. Guruswamy, L. Queimado. Role of inflammation in the development of colorectal cancer. Endocrine, Metabolic & Immune Disorders Drug Targets 2021; 21(1): 77-90.
  14. P. Zhang, Y. Tang, N.G. Li, Y. Zhu, J.A. Duan. Bioactivity and chemical synthesis of caffeic acid phenethyl ester and its derivatives. Molecules (Basel, Switzerland) 2014; 19(10): 16458-76.
  15. M.F. Tolba, H.A. Omar, S.S. Azab, A.E. Khalifa, A.B. Abdel-Naim, S.Z. Abdel-Rahman. Caffeic Acid Phenethyl Ester: A Review of Its Antioxidant Activity, Protective Effects against Ischemia-reperfusion Injury and Drug Adverse Reactions. Critical Reviews in Food Science and Nutrition 2016; 56(13): 2183-90.
  16. N. Zabaiou, A. Fouache, A. Trousson, S. Baron, A. Zellagui, M. Lahouel. Biological properties of propolis extracts: something new from an ancient product. Chemistry and Physics of Lipids 2017; 207: 214-22.
  17. I. Turan, S. Demir, S. Misir, K. Kilinc, A. Mentese, Y. Aliyazicioglu. Cytotoxic Effect of Turkish Propolis on Liver, Colon, Breast, Cervix and Prostate Cancer Cell Lines. Tropical Journal of Pharmaceutical Research 2015; 14(5): 777-82.
  18. E. Taslidere, M. Gul, H. Elbe, A. Cetin, N. Vardi, F. Ozyalin. The effects of caffeic acid phenethyl ester on streptozotocin-induced diabetic liver injury. Bratisl Lek Listy 2016; 117(5): 276-82.
  19. S. Akyol, G. Ozturk, Z. Ginis, F. Armutcu, M.R. Yigitoglu, O. Akyol. In vivo and in vitro ant\ineoplastic actions of caffeic acid phenethyl ester (CAPE): therapeutic perspectives. Nutrition and Cancer 2013; 65(4): 515-26.
  20. F. Armutcu, S. Akyol, S. Ustunsoy, F.F. Turan. Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects (Review). Experimental and Therapeutic Medicine 2015; 9(5): 1582-8.
  21. M.M. Ghorab, Z.H. Ismail, M. Abdalla. Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties. Arzneimittel-Forschung 2010; 60(2): 87-95.
  22. S.M. Abdel-Gawad, M.M. Ghorab, A.M. El-Sharief, F.A. El-Telbany, M. Abdel-Alla. Design, synthesis, and antimicrobial activity of some new pyrazolo[3,4-d] pyrimidines. Heteroatom Chemistry 2003; 14(6): 530-4.
  23. N.I. Abou-Taleb, O.A. Elblasy, E.A. Elbesoumy, H.I. Basuny, E.A. Elhamadi, M.S. Nasr eldin. Nasr eldin MS, Emara AA, Ali AA, Salem MA, Ahmed FM, Hussein MA. Mechanism of antiangiogenic and antioxidant activity of newly synthesized CAMBA in ehrlich ascites carcinoma-bearing mice. Asian Journal of Chemistry 2021; 33(10): 2465-71.
  24. R.M. Borik, M.A. Hussein. A Novel Quinazoline-4-one Derivatives as a Promising Cytokine Inhibitors: Synthesis, Molecular Docking, and Structure-activity Relationship. Current Pharmaceutical Biotechnology 2022; 23(9): 1179-203.
  25. G. Murtaza, S. Karim, M.R. Akram, S.A. Khan, S. Azhar, A. Mumtaz. Caffeic acid phenethyl ester and therapeutic potentials. BioMed Research International 2014; 2014: 145342.
  26. G. Wang, J. Wang, L. Du, M. Li. Visualization-Based Discovery of Vanin-1 Inhibitors for Colitis. Frontiers in Chemistry 2022; 9: 809495.
  27. P. Lu, C. Zhang, L. Fu, Y. Wei, Y. Huang, X. Wang. Near-Infrared Fluorescent Probe for Imaging and Evaluating the Role of Vanin-1 in Chemotherapy. Analytical Chemistry 2021; 93(29): 10378-87.
  28. L. Ling, H.T. Lu, H.F. Wang, M.J. Shen, H.B. Zhang. MicroRNA-203 Acts as a Potent Suppressor in Septic Shock by Alleviating Lung Injury via Inhibition of VNN1. Kidney & Blood Pressure Research 2019; 44(4): 565-82.
  29. N.A. Gobba, A. Hussein Ali, D.E. El Sharawy, M.A. Hussein. The potential hazardous effect of exposure to iron dust in Egyptian smoking and nonsmoking welders. Archives of Environmental & Occupational Health 2018; 73(3): 189-202.
  30. S.A. Boshra, M.A. Hussein. Cranberry extract as a supplemented food in treatment of oxidative stress and breast cancer induced by N-Methyl-N-Nitrosourea in female virgin rats. International Journal of Phytomedicine 2016; 8(2): 217-27.
  31. H.A. Elgizawy, A.A. Ali, M.A. Hussein. Resveratrol: Isolation, and Its Nanostructured Lipid Carriers, Inhibits Cell Proliferation, Induces Cell Apoptosis in Certain Human Cell Lines Carcinoma and Exerts Protective Effect Against Paraquat-Induced Hepatotoxicity. Journal of Medicinal Food 2021; 24(1): 89-100.
  32. M.A. Hussein. Synthesis of some novel triazoloquinazolines and triazinoquinazolines and their evaluation for anti-inflammatory activity. Medicinal Chemistry Research 2012; 21(8): 1876-86.
  33. H.A. Abdel Maksoud, M.G. Elharrif, M.K. Mahfouz, M.A. Omnia, M.H. Abdullah, M.E. Eltabey. Biochemical study on occupational inhalation of benzene vapours in petrol station. Respiratory Medicine Case Reports 2019; 27: 100836.
  34. Heba A El Gizawy, Heba M Abo-Salem, Ali A Ali, Mohammed A Hussein. Phenolic Profiling and Therapeutic Potential of Certain Isolated Compounds from Parkia roxburghii against AChE Activity as well as GABAA α5, GSK-3β, and p38α MAP-Kinase Genes. ACS omega 2021; 6(31): 20492-20511.
  35. R.M. Borik, M.A. Hussein. Synthesis, molecular docking, biological potentials, and structure activity relationship of new quinazoline and quinazoline-4-one derivatives. Asian Journal of Chemistry 2021; 33(2): 423-38.
  36. M. Li, X.F. Wang, J.J. Shi, Y.P. Li, N. Yang, S. Zhai. Caffeic acid phenethyl ester inhibits liver fibrosis in rats. World Journal of Gastroenterology 2015; 21(13): 3893-903.
  37. M.A. Hussein, N.E. Ismail, A.H. Mohamed, R.M. Borik, A.A. Ali, Y.O. Mosaad. Plasma Phospholipids: A Promising Simple Biochemical Parameter to Evaluate COVID-19 Infection Severity. Bioinformatics and Biology Insights 2021; 15: 11779322211055891.
  38. B. Bang, L.M. Lichtenberger. Methods of Inducing Inflammatory Bowel Disease in Mice. Curr Protoc Pharmacol 2016; 72: 5.58.1-5.58.42.
  39. Y. Kitamura, M. Suzuki, T. Tsukioka, K. Isobe, T. Tsujino, T. Watanabe. Spectrophotometric determination of platelet counts in platelet-rich plasma. International Journal of Implant Dentistry 2018; 4(1): 29.
  40. R. Metgud, C. Anandani, K. Singh. Estimation of salivary nitric oxide in oral precancer patients. Biotechnic & Histochemistry 2015; 90(4): 302-8.
  41. M.M. Nagib, M.G. Tadros, M.I. ElSayed, A.E. Khalifa. Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. Toxicology and Applied Pharmacology 2013; 271(1): 106-13.
  42. B. Gao, S. Saralamba, Y. Lubell, L. White, A.M. Dondorp, R. Aguas. Determinants of MDA impact and designing MDAs towards malaria elimination. Elife 2020; 15(9): e51773.
  43. J.B. Owen, D.A. Butterfield. Measurement of oxidized/reduced glutathione ratio. Methods in Molecular Biology (Clifton, N.J.) 2010; 648: 269-77.
  44. G. Bresciani, I.B. da Cruz, J. González-Gallego. Manganese superoxide dismutase and oxidative stress modulation. Advances in Clinical Chemistry 2015; 68: 87-130.
  45. C. Glorieux, M. Zamocky, J.M. Sandoval, J. Verrax, P.B. Calderon. Regulation of 303 catalase expression in healthy and cancerous cells. Free Radical Biology and 304 Medicine 2015; 87: 84-97.
  46. H.A. Alturkistani, F.M. Tashkandi, Z.M. Mohammedsaleh. Histological Stains: A Literature Review and Case Study. Global Journal of Health Science 2015; 8(3): 72-9.
  47. . SPSS. 2018. (SPSS 20), Inc., Chicago, IL, USA. 2018; :
  48. L. Chapuy, M. Bsat, M. Rubio, F. Harvey, V. Motta, F. Schwenter. Transcriptomic analysis and high-dimensional phenotypic mapping of mononuclear phagocytes in mesenteric lymph nodes reveal differences between ulcerative colitis and crohn's disease. Journal of Crohn's and Colitis 2020; 14(3): 393-405.
  49. N.E. Duran, D.W. Hommes. Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therapeutic Advances in Gastroenterology 2016; 9(4): 533-47.
  50. J. Geng, J. Fan, Q. Ouyang, X. Zhang, X. Zhang, J. Yu. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget 2014; 5(14): 5700-11.
  51. Q. Ji, X. Liu, X. Fu, L. Zhang, H. Sui, L. Zhou. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One 2013; 8(11): e78700.
  52. K.M. Espíndola, R.G. Ferreira, L.E. Narvaez, A.C. Silva Rosario, A.H. da Silva, A.G. Silva. Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma. Frontiers in Oncology 2019; 9: 541.
  53. B. Jeoung. lee Kd, na cS, Kim Ye, Kim B, Kim Yr. Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synoviocyte proliferation and reduces the production of proinflmmatory mediators in macrophages: the therapeutic effect of GHJTY on rheumatoid arthritis. BMC Complementary and Alternative Medicine 2013; 13: 47.
  54. J.W. O'Connor, E.W. Gomez. Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clinical and Translational Medicine 2014; 3(65): 23-34.
  55. J. Lee. Fecal calprotectin in inflammatory bowel disease. Korean J Gastroenterol 2016; 67(5): 233-237.
  56. V. Uko, S. Thangada, K. Radhakrishnan. Liver disorders in inflammatory bowel disease. Gastroenterology Research and Practice 2012; 2012(2): 642923.
  57. C. Bullich, A. Keshavarzian, J. Garssen, A. Kraneveld, P. Perez-Pardo. Gut vibes in parkinson's disease: the microbiota-gut-brain axis. Movement Disorders Clinical Practice (Hoboken, N.J.) 2019; 6(8): 639-51.
  58. L.M. da Silva, P. de Souza, S.K. Jaouni, S. Harakeh, S. Golbabapour, S.F. de Andrade. Propolis and its potential to treat gastrointestinal disorders. Evidence-Based Complementary and Alternative Medicine 2018; 2018: 2035820.
  59. H.F. Chiu, K. Venkatakrishnan, O. Golovinskaia, C.K. Wang. Gastroprotective effects of polyphenols against various gastro-intestinal disorders: A mini-review with special focus on clinical evidence. Molecules (Basel, Switzerland) 2021; 26(7): 2090.
  60. A. Santino, A. Scarano, S. De Santis, M. De Benedictis, G. Giovinazzo, M. Chieppa. Gut microbiota modulation and anti-inflammatory properties of dietary polyphenols in IBD: New and Consolidated Perspectives. Current Pharmaceutical Design 2017; 23(16): 2344-51.
  61. C. Zamora, E. Canto, J.C. Nieto, E. Garcia-Planella, J. Gordillo, M.A. Ortiz. Inverse association between circulating monocyte-platelet complexes and inflammation in ulcerative colitis patients. Inflammatory Bowel Diseases 2018; 24(4): 818-28.
  62. T. Honjo, K. Toyota, M. Kanada, T. Itoh. Vitamin C enema advances induction of remission in the dextran sodium sulfate-induced colitis model in rats. Journal of Nutritional Science and Vitaminology 2021; 67(2): 91-8.
  63. J. Kurtovic, I. Segal. Recent advances in biological therapy for inflammatory bowel disease. Tropical Gastroenterology 2004; 25(1): 9-14.
  64. R.A. Gupta, M.N. Motiwala, U.N. Mahajan, S.G. Sabre. Protective effect of Sesbania grandiflora on acetic acid induced ulcerative colitis in mice by inhibition of TNF-α and IL-6. Journal of Ethnopharmacology 2018; 219: 222-32.
  65. T. Nakashima, T. Maeda, H. Nagamoto, T. Kumakura, M. Takai, T. Mori. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Digestive Diseases and Sciences 2005; 50(S1): 124-31.
  66. A.K. Zielińska, M. Sa\laga, P. Siwiński, M. W\lodarczyk, A. Dziki, J. Fichna. Oxidative stress does Not influence subjective pain sensation in inflammatory bowel disease patients. Antioxidants 2021; 10(8): 1237.
  67. J.F. Xing, J.N. Sun, J.Y. Sun, C.Y. You, K. Dong, J. Lv. Protective effects of 3,4-oxo-isopropylidene-shikimic acid on experimental colitis induced by trinitrobenzenesulfonic acid in rats. Digestive Diseases and Sciences 2012; 57(8): 2045-54.
  68. J. Vrdoljak, M. Kumric, T. Ticinovic Kurir, I. Males, D. Martinovic, M. Vilovic. Effects of wine components in inflammatory bowel diseases. Molecules (Basel, Switzerland) 2021; 26(19): 5891.
  69. Y. Yan, P. Wang, Y. Sun, Y. Dong, J. Xing. Potential mechanisms of 3, 4-Oxo-isopropylidene-shikimic acid in ameliorating 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis in rats. Journal of Interferon & Cytokine Research 2019; 39(9): 554-63.
  70. J. Vrdoljak, M. Kumric, M. Vilovic, D. Martinovic, I.J. Tomic, M. Krnic. Effects of olive oil and its components on intestinal inflammation and inflammatory bowel disease. Nutrients 2022; 14(4): 757.
  71. T. Gensollen, C. Bourges, P. Rihet, A. Rostan, V. Millet, T. Noguchi. Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. Inflammatory Bowel Diseases 2013; 19(11): 2315-25.
  72. M.Y. Li, H.J. Luo, X. Wu, Y.H. Liu, Y.X. Gan, N. Xu. Anti-inflammatory effects of huangqin decoction on dextran sulfate sodium-induced ulcerative colitis in mice through regulation of the gut microbiota and suppression of the ras-PI3K-Akt-HIF-1α and NF-κB pathways. Frontiers in Pharmacology 2020; 10: 1552.
  73. Y. Tian, J. Xu, Y. Li, R. Zhao, S. Du, C. Lv. MicroRNA-31 Reduces inflammatory signaling and promotes regeneration in colon epithelium, and delivery of mimics in microspheres reduces colitis in mice. Gastroenterology 2019; 156(8):
  74. S. Chen, W. Zhang, C. Tang, X. Tang, L. Liu, C. Liu. Vanin-1 is a key activator for hepatic gluconeogenesis. Diabetes 2014; 63(6): 2073-85.
  75. J.Q. Qu, H.M. Yi, X. Ye, J.F. Zhu, H. Yi, L.N. Li. MiRNA-203 Reduces nasopharyngeal carcinoma radioresistance by targeting IL8/AKT signaling. Molecular Cancer Therapeutics 2015; 14(11): 2653-64.
  76. X. Yan, W. Li, L. Yang, W. Dong, W. Chen, Y. Mao. MiR-135a Protects vascular endothelial cells against ventilator-induced lung Injury by inhibiting PHLPP2 to activate PI3K/Akt pathway. Cellular Physiology and Biochemistry 2018; 48(3): 1245-58.
  77. T.C. Huang, S.S. Tsai, L.F. Liu, Y.L. Liu, H.J. Liu, K.P. Chuang. Effect of Arctium lappa L. in the dextran sulfate sodium colitis mouse model. World Journal of Gastroenterology 2010; 16(33): 4193-9.

Comments